Braveheart Bio, Inc. (BRVE) shareholders
Close on Nov 18, 2026Market cap $1.67BP/E –Yield –
Ownership
Who owns Braveheart Bio's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC Joint filing with OrbiMed Capital GP IX LLC (13.20%) | 12,175,159 | 13.50% | 13D (active) amendment | Sep 8, 2026 |
| AH Bio Fund IV, L.P. Joint filing with AH Equity Partners Bio IV, L.L.C. (11.40%), Marc L. Andreessen (11.40%) and 1 more | 10,232,420 | 11.40% | 13D (active) | Aug 7, 2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 7,420,091 | 8.20% | 13G (passive) | Sep 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (8.20%) | 7,374,365 | 8.20% | 13G (passive) | Sep 30, 2026 |
| Fhmlsp, L.P. Joint filing with Frazier Life Sciences Public Fund, L.P. (5.50%), Fhmlsp, L.L.C. (5.50%) | 4,976,457 | 5.50% | 13G (passive) | Aug 7, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Travis Murdoch | CEO and President, Director | 8,333,637 | 9.26% | Aug 7, 2026 |
| Michele A. Anderson | Chief Development Officer | 332,161 | 0.37% | Aug 7, 2026 |
| James Paul Rickey | Chief Financial Officer | 703,575 | 0.78% | Aug 7, 2026 |
| Vineeta Agarwala | Director | 10,232,420 | 11.36% | Aug 14, 2026 |
| Erez Chimovits | Director, 10% owner | 273,333 | 0.30% | Aug 11, 2026 |
| Genesis GP LLC OrbiMed | Director, 10% owner | 273,333 | 0.30% | Aug 11, 2026 |
| Capital GP IX LLC OrbiMed | Director, 10% owner | – | – | Aug 11, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | 1,102,739 | 1.22% | Aug 11, 2026 |
| David Charles Lubner | Director | 55,555 | 0.06% | Aug 7, 2026 |
| Jasper Bos | Director | – | – | Aug 7, 2026 |
| Christopher Viehbacher | Director | 759,857 | 0.84% | Aug 7, 2026 |
| Tim Lohoff | Director | – | – | Aug 7, 2026 |
| David I. Malek | Director | 1,013,297 | 1.13% | Aug 7, 2026 |
| Jason V. Coloma | Director | 1,100,456 | 1.22% | Aug 5, 2026 |
| Marc L. Andreessen | 10% owner | 9,132,420 | 10.14% | Aug 11, 2026 |
| AH Bio Fund IV, L.P. | 10% owner | – | – | Aug 11, 2026 |
| AH Equity Partners Bio IV, L.L.C. | 10% owner | – | – | Aug 11, 2026 |
| Benjamin A. Horowitz | 10% owner | – | – | Aug 11, 2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | 7,420,091 | 8.24% | Aug 10, 2026 |
| Growth Opportunities Fund III Cooperatief U.A. Forbion | 10% owner | 30,331,502 | 33.69% | Aug 7, 2026 |
| Growth III Management B.V. Forbion | 10% owner | – | – | Aug 7, 2026 |
| Ventures Fund VII Cooperatief U.A. Forbion | 10% owner | – | – | Aug 7, 2026 |
| Ventures VII Management B.V. Forbion | 10% owner | 1,102,737 | 1.22% | Aug 7, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marc L. Andreessen 10% owner | Aug 7, 2026 | Conversion | +9,132,420 | – | – | 9,132,420 |
| Marc L. Andreessen 10% owner | Aug 7, 2026 | Buy | +1,100,000 | $18.00 | $19.80M | 10,232,420 |
| Genesis GP LLC OrbiMed Director, 10% owner | Aug 7, 2026 | Buy | +273,333 | $18.00 | $4.92M | 273,333 |
| Genesis GP LLC OrbiMed Director, 10% owner | Aug 7, 2026 | Conversion | +9,132,420 | – | – | 10,235,159 |
| Genesis GP LLC OrbiMed Director, 10% owner | Aug 7, 2026 | Buy | +1,666,667 | $18.00 | $30.00M | 11,901,826 |
| Erez Chimovits Director, 10% owner | Aug 7, 2026 | Buy | +273,333 | $18.00 | $4.92M | 273,333 |
| Erez Chimovits Director, 10% owner | Aug 7, 2026 | Buy | +1,666,667 | $18.00 | $30.00M | 11,901,826 |
| Erez Chimovits Director, 10% owner | Aug 7, 2026 | Conversion | +9,132,420 | – | – | 10,235,159 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Aug 7, 2026 | Conversion | +7,420,091 | – | – | 7,420,091 |
| James Paul Rickey Chief Financial Officer | Aug 7, 2026 | Buy | +27,777 | $18.00 | $499.99K | 520,927 |
| David I. Malek Director | Aug 7, 2026 | Buy | +4,166 | $18.00 | $74.99K | 533,845 |
| Christopher Viehbacher Director | Aug 7, 2026 | Buy | +83,333 | $18.00 | $1.50M | 609,519 |
| Growth Opportunities Fund III Cooperatief U.A. Forbion 10% owner | Aug 7, 2026 | Conversion | +7,990,867 | – | – | 8,505,478 |
| Growth Opportunities Fund III Cooperatief U.A. Forbion 10% owner | Aug 7, 2026 | Buy | +1,920,000 | $18.00 | $34.56M | 11,640,546 |
| Growth Opportunities Fund III Cooperatief U.A. Forbion 10% owner | Aug 7, 2026 | Buy | +1,680,000 | $18.00 | $30.24M | 10,185,478 |
| Growth Opportunities Fund III Cooperatief U.A. Forbion 10% owner | Aug 7, 2026 | Conversion | +9,132,420 | – | – | 9,720,546 |
| Travis Murdoch CEO and President, Director | Aug 7, 2026 | Buy | +83,333 | $18.00 | $1.50M | 2,940,670 |
| David Charles Lubner Director | Aug 7, 2026 | Buy | +55,555 | $18.00 | $999.99K | 55,555 |
| Michele A. Anderson Chief Development Officer | Aug 7, 2026 | Buy | +1,111 | $18.00 | $20.00K | 332,161 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 3 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Braveheart Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 106,028 shares on Oct 1, 2026 over the last 90 days.
See a number that looks wrong?